TNFSF10 and cancer: Extensive preclinical studies conducted on recombinant human TRAIL (rhTRAIL) and TRAIL receptor agonists (TRAs) against TRAIL-receptors have demonstrated successful results with safety and tolerance even at high-dose administration to cancer patients.